ArticlePharmaceutics2011
Nano delivers big: designing molecular missiles for cancer therapeutics.
Article in Pharmaceutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- What is the Reason That the Pharmacological Future of Chemotherapeutics in the Treatment of Lung Cancer Could Be Most Closely Related to Nanostructures? Platinum Drugs in Therapy of Non-Small and Small Cell Lung Cancer and Their Unexpected, Possible Interactions. The Review.International journal of nanomedicine · 2024Review
- Synthesis of Hyaluronic Acid-Conjugated FeMicromachines · 2021Article
- Article
- Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?Bioconjugate chemistry · 2016Review
- Super enhanced permeability and retention (SUPR) effects in tumors following near infrared photoimmunotherapy.Nanoscale · 2016Review
- Charge-reversal nanoparticles: novel targeted drug delivery carriers.Acta pharmaceutica Sinica. B · 2016Review
- Cancer drug delivery: considerations in the rational design of nanosized bioconjugates.Bioconjugate chemistry · 2014Review
- Safe clinical use of carbon nanotubes as innovative biomaterials.Chemical reviews · 2014Review
- Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?Theranostics · 2013Review
- Assessing DNA Damage from Enzyme-Oxidized Single-Walled Carbon Nanotubes.Toxicology research · 2013Article
- Article
- Efficient Gene Silencing by Self-Assembled Complexes of siRNA and Symmetrical Fatty Acid Amides of Spermine.Pharmaceutics · 2011Article
- Improvement of intratumor microdistribution of PEGylated liposome via tumor priming by metronomic S-1 dosing.International journal of nanomedicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Current first-line treatments for most cancers feature a short-list of highly potent and often target-blind interventions, including chemotherapy, radiation, and surgical excision. These treatments wreak considerable havoc upon non-cancerous tissue and organs, resulting in deleterious and sometimes fatal side effects for the patient. In response, this past decade has witnessed the robust emergence of nanoparticles and, more relevantly, nanoparticle drug delivery systems (DDS), widely touted as the panacea of cancer therapeutics. While not a cure, nanoparticle DDS can successfully negotiate the clinical payoff between drug dosage and side effects by encompassing target-specific drug delivery strategies. The expanding library of nanoparticles includes lipoproteins, liposomes, dendrimers, polymers, metal and metal oxide nano-spheres and -rods, and carbon nanotubes, so do the modes of delivery. Importantly, however, the pharmaco-dynamics and -kinetics of these nano-complexes remain an urgent issue and a serious bottleneck in the transition from bench to bedside. This review addresses the rise of nanoparticle DDS platforms for cancer and explores concepts of gene/drug delivery and cytotoxicity in pre-clinical and clinical contexts.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.